Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VZV-7D is a live attenuated varicella (chickenpox) vaccine developed by Beijing Wantai Biopharmaceutical. It is formulated as a lyophilized (freeze-dried) preparation containing an attenuated strain of the varicella-zoster virus (VZV), designed to stimulate an immune response and confer protection against primary infection with VZV, which causes chickenpox. The mechanism of action involves immunostimulation—exposure to the weakened virus prompts the body’s immune system to produce protective antibodies and cellular immunity against VZV. This product is in late-stage clinical development for the prevention of chickenpox[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vzv-7d.